REDWOOD CITY, Calif.,
Feb. 3, 2020 /PRNewswire/
-- Nevro Corp. (NYSE: NVRO), a global medical device
company that is providing innovative, evidence-based solutions for
the treatment of chronic pain, today announced that the Company
will release its financial results for the fourth quarter and full
year ended December 31, 2019 after
the market closes on February 25,
2020.
Investors interested in listening to the conference call may do
so by dialing (833) 286-5807 in the U.S. or (647) 689-4452
internationally, using Conference ID: 1864387. In addition, a
live webcast, as well as an archived recording, will be available
on the "Investors" section of the Company's website at:
www.nevro.com.
About Nevro
Headquartered in Redwood City, California, Nevro is a global
medical device company focused on providing innovative products
that improve the quality of life of patients suffering from
debilitating chronic pain. Nevro has developed and commercialized
the Senza spinal cord stimulation (SCS) system, an evidence-based,
non-pharmacologic neuromodulation platform for the treatment of
chronic pain. HF10 therapy has demonstrated the ability to reduce
or eliminate opioids in ≥65% of patients across six peer-reviewed
clinical studies. The Senza® System, Senza II™ System,
and the Senza® Omnia™ System are the only SCS
systems that deliver Nevro's proprietary HF10® therapy.
Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are
trademarks of Nevro Corp.
To learn more about Nevro, connect with us on LinkedIn, Twitter,
Facebook and Instagram.
Investor Relations:
Juliet
Cunningham
Vice President, Investor Relations
650-433-3247
ir@nevro.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nevro-to-report-fourth-quarter-and-full-year-2019-financial-results-300997341.html
SOURCE Nevro Corp.